| 영문 | malignant melanoma | 한글 | 악성흑색종 |
|---|---|---|---|
| 설명 | 피부에서 생기는 암의 일종. 주로 백인에게 호발하며, 50대~70대에 많이 발생하고, 젊은 여성에게 증가하는 경향이 있으며, 피부암중 1~3%를 차지하는 드문 병으로 피부와 기타 기관의 멜라닌 세포계에서 유래하는 악성종양이다. 원인으로 일광노출과 직접적인 관계가 있으며 가족적 발생도 볼 수 있다. |
||
| 영문 | magnetic resonance imaging(MRI) | 한글 | 자기공명영상 |
|---|---|---|---|
| 설명 | 인체의 장기나, 병적인 모양, 종양의 위치, 림프절의 비대 등에 대한 진단을 내리기 위해 시행하는 방사선학적인 검사방법이다. 현재 많이 쓰이고 있는 컴퓨터단층촬영술(CT: computerized tomography)과는 다른 방법으로 시행하며, 그 해상도가 컴퓨터단층촬영보다는 뛰어나 비록 고가이긴 하지만, 많이 쓰이고 있다. 또한 인체에 무해하고, 여러 가지 면에서 사람을 단층으로 분리시켜 볼 수 있는 등 장점이 많다. 단점은 심장박동기를 설치한 사람이나, 주위에 장을 띠는 물체를 몸에 지니고 있는 중환자 등에서는 이용할 수 없고, 복부장기에 대한 진단에는 컴퓨터단층촬영보다 불리한 것으로 되어 있으며, 무엇보다 설치비와 그 시술비가 비싸다는데 가장 큰 단점이 있다. |
||
| 영문 | malignant tumor | 한글 | 악성종양 |
|---|---|---|---|
| 설명 | 정상적인 조직 세포가 각종 물리적-화학적-생물학적인 발암 물질의 작용 또는 요인에 의해 돌연변이를 일으켜서 형성되는 종양. 무제한의 세포분열로 매우 왕성하게 증식하여 주위조직을 파괴-침식한다. 또 어떤 화학물질을 내어 주위의 조직세포를 침해할 뿐만 아니라, 혈관 및 림프관을 따라 전이하여 전신의 카켁시아를일으켜 죽음을 초래한다. 상피성인 것을 암종이라 하고, 비상피성인 것을 육종이라 한다. |
||
| MM | macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle... |
|---|---|
| MH | malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam... |
| MHS | major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m... |
| CMM | cell-mediated mutagenesis; cutaneous malignant melanoma |
| HCMM | hereditary cutaneous malignant melanoma |
| CMM | Cutaneous malignant melanoma |
|---|---|
| DMM | Desmoplastic Malignant Melanoma |
| MM | Malignant Melanoma |
| MMM | Metastatic malignant melanoma |
| 67Ga | Gallium |
| malignant melanoma: gallium imaging | <radiology> Greater than50% sensitivity for primary and metastatic sites: 73% sensitivity if lesion is greater than 2 cm, 17% sensitivity if less than 2 cm, see: gallium: indications malignant melanoma (12 Dec 1998) |
|---|
| bone: gallium imaging | <radiology> Increased activity in: active osteomyelitis (90% sensitivity: better than Tc-99m MDP), sarcoma, cellulitis, septic arthritis, rheumatoid arthritis, Paget disease, metastases (65% sensitivity: than for bone agents) see: gallium: indications (12 Dec 1998) |
|---|---|
| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
| inflammation: gallium imaging | <radiology> Pathophysiology: leakage of protein-bound Ga-67 into extracellular space secondary to increased capillary permeability, Ga-67 is preferentially bound to nonviable PMNs and macrophages, leukocyte incorporation (rich in lactoferrin), bacterial uptake (siderophores), inflammtory tissue stimulates lactoferrin production for chronic abdominal inflammation: 67% sensitivity; 64% specificity; 13% false negatives; 5% false positive, dose: 5 mCi; imaging: 24, 48, 72 hours, diffuse uptake in peritonitis, localised uptake in acute pyogenic abscess, phlegmon, acute cholecystitis, acute pancreatitis, acute gastritis, diverticulitis, inflammatory bowel disease, surgical wound, pyelonephritis, perinephric abscess see: gallium indications, gallium vs. Indium (12 Dec 1998) |
| kidney: gallium imaging | <radiology> 10-20% of Ga-67 excreted via GU tract; no renal activity after 24hrs abnormal uptake (images at 48-72 hrs): tumour, primary renal tumour (variable uptake), lymphoma/leukaemia, metastases (e.g., melanoma), inflammation, acute pyelonephritis (88% sensitivity); abscess, lobar nephroma, others, collagen vascular disease, vasculitis, Wegener granulomatosis, amyloidosis, haemochromatosis, hepatic failure, antineoplastic drugs, transplant rejection: acute, chronic, ATN see also: gallium: indications (12 Dec 1998) |
| lung: gallium imaging | <radiology> Scans at 48 hrs because 50% of normals show activity at 24 hrs, focal uptake, primary pulmonary malignancy, benign disorder: granuloma, abscess, pneumonia, silicosis, multifocal/diffuse uptake, infection, TB: active lesion, miliary TB, rapidly progressive TB pneumonia, PCP: unimpressive symptoms and CXR, CMV, inflammation: sarcoid, interstitial lung disease (pneumoconiosis, idiopathic pulmonary fibrosis, lymphangitic carcinomatosis), radiation pneumonitis, drugs: bleomycin, amiodarone, contrast lymphangiography (in 50%) see: gallium: indications, uptake with normal chest film (12 Dec 1998) |
| cancer, malignant melanoma | A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma. (12 Dec 1998) |
| malignant lentigo melanoma | <tumour> A melanoma arising from a malignant lentigo. (05 Mar 2000) |
| malignant melanoma | <oncology, tumour> A malignant tumour which arises from the pigment producing cells (melanosomes) of the deeper layers of the skin (or the eye). Melanoma is the leading cause of death attributable to skin lesions. Described as an irregular dark skin lesion that may have areas of varying colour. Often greater than 6 mm in diameter. (27 Sep 1997) |
| malignant melanoma in situ | A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ. (05 Mar 2000) |
| malignant melanoma: staging | <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma (12 Dec 1998) |
| desmoplastic malignant melanoma | <tumour> A melanoma with marked fibrosis surrounding atypical spindle-shaped melanocytes in the dermis. (05 Mar 2000) |
| gallium | <chemistry, element> A rare metallic element, found in certain zinc ores. It is white, hard, and malleable, resembling aluminium, and remarcable for its low melting point (86 F, 30C). The element was predicted with most of its properties, under the name ekaluminium, by the Russian chemist Mendelejeff, on the basis of the Periodic law. This prediction was verified in its discovery by the French chemist Lecoq de Boisbaudran by its characteristic spectrum (two violet lines), in an examination of a zinc blende from the Pyrenees. Atomic weight: 69.9 Abbreviation: Ga Origin: NL, fr. L. Gallia France. Source: Websters Dictionary (01 Mar 1998) |
| gallium-67 | A cyclotron-produced radionuclide with a half-life of 3.260 days and major gamma ray emissions of 93, 185, and 300 kiloelectron volts; used in the citrate form as a tumour-and inflammation-localizing radiotracer. (05 Mar 2000) |
| gallium-67 citrate | <radiology> Analogue of ferric iron, decay: by electron capture to ground state of Zn-67, energy levels: 92 KeV (40%); 184 KeV (23%); 296 KeV (21%), physiological half life: 3.3 days (78 hr), biological half life: 2-3 weeks, binding sites: serum: transferrin, haptoglobin, albumin, globulins, tissue: lactoferrin, PMN's (viable and nonviable), lymphocytes, macrophages, bacteria and fungi, tumour cell-associated transferrin receptor see: gallium: indications (12 Dec 1998) |
| gallium-68 | A positron emitter with a radioactive half-life of 1.130 hours. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|